V
Valerio De Stefano
Researcher at The Catholic University of America
Publications - 316
Citations - 11591
Valerio De Stefano is an academic researcher from The Catholic University of America. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 45, co-authored 268 publications receiving 9674 citations. Previous affiliations of Valerio De Stefano include Casa Sollievo della Sofferenza & Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Antonio Palumbo,Sara Bringhen,Tommaso Caravita,Emanuela Merla,Vincenzo Capparella,Vincenzo Callea,Clotilde Cangialosi,Mariella Grasso,Fausto Rossini,Monica Galli,Lucio Catalano,Elena Zamagni,Maria Teresa Petrucci,Valerio De Stefano,Manuela Ceccarelli,Maria Teresa Ambrosini,Ilaria Avonto,Patrizia Falco,Giovannino Ciccone,Anna Marina Liberati,Pellegrino Musto,Mario Boccadoro +21 more
TL;DR: Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma and anticoagulant prophylaxis reduces frequency of thrombosis.
Journal ArticleDOI
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Giorgina Specchia,Rossella R. Cacciola,Riccardo Cavazzina,Daniela Cilloni,Valerio De Stefano,Elena Maria Elli,Alessandra Iurlo,Roberto Latagliata,Francesca Lunghi,Monia Lunghi,Rosa Maria Marfisi,Pellegrino Musto,Arianna Masciulli,Caterina Musolino,Nicola Cascavilla,Giovanni Quarta,Maria Luigia Randi,Davide Rapezzi,Marco Ruggeri,Elisa Rumi,Anna Rita Scortechini,Simone Santini,Marco Scarano,Sergio Siragusa,Antonio Spadea,Alessia Tieghi,Emanuele Angelucci,Giuseppe Visani,Alessandro M. Vannucchi,Tiziano Barbui +31 more
TL;DR: In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with an intended target of 45 to 50%.
Journal ArticleDOI
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Alessandro M. Vannucchi,Elisabetta Antonioli,Paola Guglielmelli,Alessandro Rambaldi,Giovanni Barosi,Roberto Marchioli,Rosa Maria Marfisi,Guido Finazzi,Vittoria Guerini,Fabrizio Fabris,Maria Luigia Randi,Valerio De Stefano,Sabrina Caberlon,Agostino Tafuri,Marco Ruggeri,Giorgina Specchia,Vincenzo Liso,Edoardo Rossi,Enrico Pogliani,Luigi Gugliotta,Alberto Bosi,Tiziano Barbui +21 more
TL;DR: It is concluded that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET.
Journal ArticleDOI
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry
Guido Finazzi,Vincenzo Brancaccio,Marco Moia,N. Ciavarella,M. Gabriella Mazzucconi,Piercarla Schinco,Marco Ruggeri,Enrico Pogliani,Gabriella Gamba,Edoardo Rossi,Francesco Baudo,Cesare Manotti,Armando D'Angelo,Gualtiero Palareti,Valerio De Stefano,M. Berrettini,Tiziano Barbui +16 more
TL;DR: The present study shows that previous thrombosis and ACA titer > 40 U are independent predictors of thromBosis; history of miscarriage or vascular disease is significantly associated with adverse pregnancy outcome; and hematological malignancies can develop during follow-up in patients with antiphospholipid antibodies.
Journal ArticleDOI
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
Tiziano Barbui,Guido Finazzi,Alessandra Carobbio,Juergen Thiele,Francesco Passamonti,Elisa Rumi,Marco Ruggeri,Francesco Rodeghiero,Maria Luigia Randi,Irene Bertozzi,Heinz Gisslinger,Veronika Buxhofer-Ausch,Valerio De Stefano,Silvia Betti,Alessandro Rambaldi,Alessandro M. Vannucchi,Ayalew Tefferi +16 more
TL;DR: The 3-tiered new prognostic model, devised in an international study of 891 patients with essential thrombocythemia, outperformed conventional risk stratification in predicting future vascular events.